Testing XNW5004 tablets for relapsed T-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new tablet, XNW5004, for people with peripheral T-cell lymphoma that has come back or hasn't responded to at least two prior treatments. The goal is to see if it can help shrink tumors or stop the cancer from growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have peripheral T-cell lymphoma that has returned or not improved after at least two prior treatments.
- You have at least one tumor that can be measured on scans.
- You have an ECOG performance status of 0 or 1 (able to carry out daily activities without help).
- You are willing to provide a tumor tissue sample (archived or fresh).
- You have not taken an EZH2 inhibitor before (a type of targeted drug).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new oral tablet called XNW5004 for people with peripheral T-cell lymphoma (a type of blood cancer) that has come back or not responded to prior treatments. The goal is to see if this drug can help shrink tumors or slow the disease.
This study tests two new drugs (SHR-0302 and SHR-2554) for people with a type of lymphoma (peripheral T-cell lymphoma) that has come back or not responded to prior treatment. The goal is to see if the combination can help control the cancer.
This trial tests a new drug called XNW5004 combined with standard chemotherapy for people who have just been diagnosed with peripheral T-cell lymphoma and haven't had treatment yet. The goal is to see if adding XNW5004 helps more than chemotherapy alone.
This study tests a new tablet called XNW5004 in patients with follicular lymphoma (a type of blood cancer) that has come back or stopped responding after multiple prior treatments. The goal is to see if this drug can help control the cancer in patients who have limited options.
This trial is testing several new drug combinations for people with peripheral T-cell lymphoma that has come back or not responded to treatment. It aims to find new options that may work better.
This trial tests an experimental drug, SAR448501/DR-0201, for people with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior treatments. The goal is to see if the drug is safe and can shrink tumors.
Hear when a new Relapsed/Refractory Peripheral T Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.